Biotech | April 06, 2022
BioFluidica to introduce next-generation biomarker isolation platform
BioFluidica LiquidScan harnesses the power of microfluidics
BioFluidica LiquidScan harnesses the power of microfluidics
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
BVX-0922 to target colorectal cancer under investigator-sponsored IND
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The expansion makes Exothera one of the largest viral vector facilities in Europe
Subscribe To Our Newsletter & Stay Updated
